CRISPR Therapeutics director Simeon George reports sale of shares worth $720,373.362

CRSP•2026-10-16

Director Simeon George sold 14,514 CRISPR Therapeutics common shares on October 14, 2026, at $49.633 per share, and exercised options for 30,000 shares at $14 each.

1. Share transactions

Following the transactions, George directly owned 15,486 common shares and indirectly held 2,038,763 common shares.

Sources

CRISPR Therapeutics director Simeon George reports sale of shares worth $720,373.362

Sec

CRISPR Therapeutics director Simeon George reports sale of shares worth $720,373.362

1. Share transactions

Related News

Asure Software enters credit agreement on October 15, 2026

Woodward appoints Paxton McVoy as chief information officer

Fossil Group awards CFO Randy Greben 65,217 restricted stock units

Sources

CRISPR Therapeutics director Simeon George reports sale of shares worth $720,373.362

Celanese announces global price increases for liquid crystal polymer products

Ethos Technologies President Wang Lingke reports sale of $4.54 million in common shares